Anakinra

About Hamlet Biopharma

Hamlet Biopharma is a clinical-stage biotech advancing a novel oncology platform and repurposed immunology assets. Its lead candidate, Alpha1H, derived from the HAMLET complex, has shown promising efficacy in Phase II for non-muscle invasive bladder cancer (NMIBC). The company is also developing anakinra for recurrent urinary tract infections (rUTI) and severe bladder pain, having completed successful Phase II studies. Based in Lund, Sweden, Hamlet appears to be a publicly-traded, pre-revenue entity preparing for Phase III trials.

About Hamlet Biopharma

Hamlet Biopharma is a clinical-stage biotech advancing a novel oncology platform and repurposed immunology assets. Its lead candidate, Alpha1H, derived from the HAMLET complex, has shown promising efficacy in Phase II for non-muscle invasive bladder cancer (NMIBC). The company is also developing anakinra for recurrent urinary tract infections (rUTI) and severe bladder pain, having completed successful Phase II studies. Based in Lund, Sweden, Hamlet appears to be a publicly-traded, pre-revenue entity preparing for Phase III trials.

Therapeutic Areas